Tobramycin

Manufacturer
MWI | Akorn Operating Company LLC | Akorn
Effective date
2022-02-07
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
5
Source
full-release
Hydrated at
2026-05-31 20:39:57

Label at a glance#

ProductTobramycin
Active ingredientTobramycin
Label structure13 sections

Indications and uses

Tobramycin ophthalmic solution 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution. Clinical studies have shown tobramycin to be safe and effective for use in children.

Dosage and administration

In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

Storage and handling

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep container tightly closed. Protect from excessive heat." apexa ™ Manufactured by: Akorn Lake Forest, IL 60045 Distributed by: MWI Boise, ID 83705" MWTM00N            Rev. 09/21

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

STERILE

Rx Only

DESCRIPTION:

DESCRIPTION SECTION

Tobramycin Ophthalmic Solution USP, 0.3% is a sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of external ophthalmic infections.

Each mL contains:

Active: tobramycin 0.3% (3 mg). Inactives: boric acid, sodium chloride, sodium sulfate, tyloxapol, sodium hydroxide and/or sulfuric acid to adjust pH (7.0 to 8.0), and water for injection. Preservative: benzalkonium chloride 0.01% (0.1 mg).

Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens.

The chemical structure of tobramycin is:

Molecular Weight = 467.52

Molecular Formula: C18H37N5O9

Chemical Structure of Tobramycin
Chemical Structure of Tobramycin

Chemical Name: O-{3-amino-3-deoxy-β-D-gluco-pyranosyl (1→4)}-O-{2,6-diamino 2, 3, 6-trideoxy-α-D-ribohexo-pyranosyl-(1→6)}-2-deoxystreptamine.

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

In Vitro Data: In Vitro studies have demonstrated tobramycin is active against susceptible strains of the following microorganisms:

Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains.

Streptococci, including some of the Group A beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae.

Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.

INDICATIONS AND USAGE:

INDICATIONS & USAGE SECTION

Tobramycin ophthalmic solution 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution. Clinical studies have shown tobramycin to be safe and effective for use in children.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

Tobramycin ophthalmic solution 0.3% is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS:

WARNINGS SECTION

FOR TOPICAL OPHTHALMIC USE ONLY. NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If a sensitivity reaction to tobramycin ophthalmic solution 0.3% occurs, discontinue use.

PRECAUTIONS:

PRECAUTIONS SECTION

GENERAL PRECAUTIONS SECTION

General: As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated.

Cross-sensitivity to other aminoglycoside antibiotics may occur; if hypersensitivity develops with this product, discontinueuse and institute appropriate therapy. Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.

INFORMATION FOR PATIENTS SECTION

Information for Patients: Do not touch dropper tip to any surface, as this may contaminate the solution.

PREGNANCY SECTION

Pregnancy Category B: Reproduction studies in 3 types of animals at doses up to 33 times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

NURSING MOTHERS SECTION

Nursing Mothers: Because of the potential for adverse reactions in nursing infants from tobramycin, a decision should be made whether to discontinue nursing the infant or discontinue the drug, taking into account the importance of the drug to the mother.

PEDIATRIC USE SECTION

Pediatric Use: Safety and effectiveness in pediatric patients below the age of 2 months has not been established.

GERIATRIC USE SECTION

Geriatric Use: No overall clinical differences in safety or effectiveness have been observed between the elderly and other adult patients.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

The most frequent adverse reactions to tobramycin ophthalmic solution 0.3% are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with tobramycin.

SPL UNCLASSIFIED SECTION

Postmarketing Experience: Additional adverse reactions identified from postmarketing use include anaphylactic reaction, Stevens-Johnson syndrome, and erythema multiforme.

The following additional adverse reactions have been reported with systemic aminoglycosides: Neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. Aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson's disease, because of their potential effect on neuromuscular function.

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

HOW SUPPLIED:

HOW SUPPLIED SECTION

Tobramycin Ophthalmic Solution USP, 0.3% is supplied as a sterile solution in white low-density polyethylene (LDPE) plastic dropper bottle:

NDC 13985-604-05            5 mL

STORAGE:

STORAGE AND HANDLING SECTION

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep container tightly closed. Protect from excessive heat."

apexa™
Manufactured by: Akorn
Lake Forest, IL 60045

Distributed by: MWI
Boise, ID 83705"
MWTM00N            Rev. 09/21

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Container Label:

NDC 13985-604-05

Tobramycin Ophthalmic

Solution, USP 0.3%

FOR TOPICAL

OPHTHALMIC USE ONLY.

Apexa logo

STERILE

Rx Only

AP 704006 5 mL

Principal Display Panel Text for Container Label
Principal Display Panel Text for Container Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Carton Label:

NDC 13985-604-05

Tobramycin

Ophthalmic

Solution, USP 0.3%

STERILE

Rx Only

Apexa logo

AP 704006 5 mL

Principal Display Panel Text for Carton Label
Principal Display Panel Text for Carton Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
313415tobramycin 0.3 % Ophthalmic SolutionPSN5
313415tobramycin 3 MG/ML Ophthalmic SolutionSCD5
313415tobramycin 0.3 % Ophthalmic SolutionSY5

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
TOBRAMYCIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
f297c7c1-845a-4369-8c02-c51b92d6ae8eProduct name320240725
551d952d-4ce2-24f0-9ab0-630ad9aae596Product name220231211
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
941f67d9-7f03-56d2-750c-36de24f654dbProduct name320221117
9cfa145f-dbe9-bc02-83c2-692786ef6676Product name920210928
2f9713b8-5e7e-bbcc-b364-1b2c27a63796Product name420210903
32a533bc-01c7-2b9f-bbf7-ecfb0d964277Product name420210625
9f5124fb-08b0-4c3e-8e12-a1a6ff310cbaProduct name120150309
745a62af-e1c0-4ca3-6d6e-2b6455b903beProduct name120140508
9ea85abb-fa68-5da6-ab60-2c7eef579000Product name120140508
aa1cd319-ece7-51f7-3a9d-52a64f5f4e81Product name120140508
d029211e-5e6b-725f-3696-ac6ff77da222Product name120140508
ef5b7aed-2b01-3ba8-5a1c-3bc9c9f03bb1Product name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
13985-604-052024-01-30C16284748780-11030e365-4a66-111a-e063-dadaa90a10e249dbd938-6c66-4835-af7f-923267f4568d

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
13985-604-05Tobramycin1 in 1 CARTONSOLUTION/ DROPS15
13985-604-05Tobramycin5 mL in 1 BOTTLE, DROPPERSOLUTION/ DROPS55

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
13985-604TOBRAMYCIN SOLUTION/ DROPS [MWI]5Legacy NDC, 2 package rows20220208_49dbd938-6c66-4835-af7f-923267f4568d.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
TobramycinACTIVE INGREDIENTVZ8RRZ51VK1
TobramycinACTIVE MOIETYVZ8RRZ51VK1
Benzalkonium ChlorideINACTIVE INGREDIENTF5UM2KM3W71
Boric AcidINACTIVE INGREDIENTR57ZHV85D41
Sodium ChlorideINACTIVE INGREDIENT451W47IQ8X1
Sodium HydroxideINACTIVE INGREDIENT55X04QC32I1
Sodium SulfateINACTIVE INGREDIENT0YPR65R21J1
Sulfuric AcidINACTIVE INGREDIENTO40UQP6WCF1
TyloxapolINACTIVE INGREDIENTY27PUL9H561
WaterINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
13985-60413985-604-05

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 7 · 392 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INTRA-ARTERIAL278 mgExact identifier — unii candidate
134 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IEMULSION / OPHTHALMIC0.02 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XINJECTION / ENDOTRACHEAL68 mgExact identifier — unii candidate
134 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRA-ARTICULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / OPHTHALMIC0.05 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XINJECTION / RETROBULBAR648 mgExact identifier — unii candidate
134 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IGEL / VAGINAL20 mgExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISPRAY / NASALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRA-ARTICULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XSYSTEM / TOPICAL3.1 mgExact identifier — unii candidate
134 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ILIQUID / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / PARENTERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XSOLUTION / TOPICAL210 mgExact identifier — unii candidate
134 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IENEMA / RECTAL0.44 %v/vExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IAEROSOL, FOAM / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ITABLET, ORALLY DISINTEGRATING / ORAL1 mgExact identifier — unii candidate
174 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XINJECTION / PERINEURAL648 mgExact identifier — unii candidate
134 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION / ENDOTRACHEAL7.6 mgExact identifier — unii candidate
134 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SUSPENSION/ DROPS / OPHTHALMIC0.02 %w/vExact identifier — unii candidate
24 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRA-ARTERIAL176 mgExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRASPINALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRAVASCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISUSPENSION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XPOWDER / TOPICALNAExact identifier — unii candidate
134 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XINJECTION / EPIDURAL648 mgExact identifier — unii candidate
134 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INTRACARDIAC70 mgExact identifier — unii candidate
134 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SUSPENSION/ DROPS / TOPICALNAExact identifier — unii candidate
24 equally ranked IID candidates
Sulfuric AcidSULFURIC ACIDO40UQP6WCFINJECTION, POWDER, FOR SOLUTION / INTRAVENOUSADJ PHExact identifier — unii candidate
28 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ICREAM / VAGINAL0.19 %w/wExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRADERMALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sulfuric AcidSULFURIC ACIDO40UQP6WCFINJECTION / INTRATHECALADJ PHExact identifier — unii candidate
28 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XDROPS / ORALNAExact identifier — unii candidate
134 equally ranked IID candidates
Sodium SulfateSODIUM SULFATE0YPR65R21JTABLET, COATED / ORALNAExact identifier — unii candidate
7 equally ranked IID candidates
Boric AcidBORIC ACIDR57ZHV85D4SUSPENSION/ DROPS / OPHTHALMIC22 mgExact identifier — unii candidate
17 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SUSPENSION / INTRASYNOVIAL4 mgExact identifier — unii candidate
134 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ICAPSULE, DELAYED RELEASE / ORAL0.25 mgExact identifier — unii candidate
174 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XLIQUID / INTRAMUSCULAR17 mgExact identifier — unii candidate
134 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / SUBCONJUNCTIVALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XSOLUTION / OPHTHALMIC13 mgExact identifier — unii candidate
134 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IGEL / TRANSDERMAL472 mgExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRAPERITONEALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Boric AcidBORIC ACIDR57ZHV85D4MOUTHWASH / BUCCAL7.36 mg/1mlExact identifier — unii candidate
17 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRATUMORADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / EPIDURALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IPOWDER, FOR SOLUTION / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
TyloxapolTYLOXAPOLY27PUL9H56SUSPENSION/ DROPS / AURICULAR (OTIC)0.05 %w/vExact identifier — unii candidate
8 equally ranked IID candidates
Boric AcidBORIC ACIDR57ZHV85D4DROPS / OPHTHALMIC1 %w/wExact identifier — unii candidate
17 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INTRACAVITARY0.82 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRA-AMNIOTICADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ILIQUID / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION / RESPIRATORY (INHALATION)43 mgExact identifier — unii candidate
134 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SPRAY / NASAL1 mgExact identifier — unii candidate
24 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / ORAL9120 mgExact identifier — unii candidate
174 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR360 mgExact identifier — unii candidate
134 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRASYNOVIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
Sodium ChlorideSODIUM CHLORIDE451W47IQ8XSPRAY / NASAL30 mgExact identifier — unii candidate
134 equally ranked IID candidates
Sodium HydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / INTRAVASCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A064096-001AKTOBTOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-31

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-3184e616aacf4f…
2026-08-18 06:07:402026-07A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-31caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-31011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-3131067a03dcf5…
2025-08-23 18:47 UTC2025-08A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-316a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-31fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-31b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-3103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-312680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-315bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-31d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-31d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-3179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-31301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-311e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-318072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMICAT1996-01-315c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMICAT1996-01-315d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMICAT1996-01-314b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMICAT1996-01-3174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMICAT1996-01-31bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMICAT1996-01-31782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMICAT1996-01-3187673890dc5c…
2021-03-12 10:30 UTC2021-03A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMICAT1996-01-315aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMICAT1996-01-318869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMICAT1996-01-31c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMICAT1996-01-313f01610625f2…
2019-09-15 20:21 UTC2019-09A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMICAT1996-01-31b00525d2431f…
2019-07-19 19:46 UTC2019-07A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMICAT1996-01-31ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-316a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-311c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-31ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-31a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-319b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-31a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-313f0d92c62455…
2023-05-13 08:27 UTC2023-05A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMIC1996-01-31053a50430f4f…
2023-01-26 05:58 UTC2023-01A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMICAT1996-01-313bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMICAT1996-01-313a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064096-001AKTOB0.3%SOLUTION/DROPS / OPHTHALMICAT1996-01-31f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064096-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064096-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064096-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064096-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064096-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064096-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064096-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A064096-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064096-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064096-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064096-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A064096-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A064096-001AT1ea99ee380514…
2023-01-26 05:58 UTC2023-01A064096-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064096-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064096-001AT1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A064096-001AT1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A064096-001AT1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
2cf0b9a2-7c56-409e-8739-f3ed34fcb0d649dbd938-6c66-4835-af7f-923267f4568d2022-02-07Warnings, Adverse reactionsExact identifier
spl id: 2cf0b9a2-7c56-409e-8739-f3ed34fcb0d6
spl set id: 49dbd938-6c66-4835-af7f-923267f4568d

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.